This is a working overview of Melanotan II, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-05 and is reviewed periodically as new material appears.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
In the Peninsular War, Arthur Wellesley, 1st Duke of Wellington, renewed the Anglo-Portuguese advance into Spain just after New Year in 1812, besieging and capturing the fortified towns of Ciudad Rodrigo, Badajoz, and crushing a French army at the Battle of Salamanca. As the French regrouped, the Anglo-Portuguese entered Madrid and advanced towards Burgos, before retreating all the way to Portugal when renewed French concentrations threatened to trap them. As a consequence of the Salamanca campaign, the French were forced to end their long siege of Cádiz and to permanently evacuate the provinces of Andalusia and Asturias. In a strategic move, Wellesley planned to move his supply base from Lisbon to Santander. The Anglo-Portuguese forces swept northwards in late May and seized Burgos. On 21 June, at Vitoria, the combined Anglo-Portuguese and Spanish armies won against Joseph Bonaparte, finally breaking French power in Spain. The French had to retreat from the Iberian peninsula, over the Pyrenees. The belligerents declared an armistice from 4 June 1813 (continuing until 13 August) during which time both sides attempted to recover from the loss of approximately a quarter of a million men in the preceding two months. During this time coalition negotiations finally brought Austria out in open opposition to France. Two principal Austrian armies took the field, adding 300,000 men to the coalition armies in Germany. The Allies now had around 800,000 front-line soldiers in the German theatre, with a strategic reserve of 350,000 formed to support the front-line operations.
== Epidemiology == The current estimated global incidence annually is 20,000 to 50,000 people, though a large number of cases are believed to go unreported. Due to the limited habitats of ciguatoxin-producing microorganisms, ciguatera is common only in subtropical and tropical waters, particularly the Pacific and Caribbean, and usually is associated with fish caught in tropical reef waters. Exportation of reef fish, as well as tourism, often account for cases that develop in other regions. Ciguatoxin is found in over 400 species of reef fish. Avoiding consumption of all reef fish is the only sure way to avoid exposure. Imported fish served in restaurants may contain the toxin and produce illness which often goes unexplained by physicians unfamiliar with the symptoms of a tropical toxin. Ciguatoxin can also occur in farm-raised salmon. Furthermore, species substitution, labeling a reef fish as a non-reef fish at restaurants and retail, can complicate efforts by consumers to avoid ciguatera.
The bacteria can grow in a number of artificial nutrient environments, especially betaine- and arginine-containing ones. In vitro, optimal proliferation temperature is reported around 40 °C in neutral or slightly acidic environments (pH 6.8–7.0). The majority of strains are capable of oxidation, not fermentation, of sugars without gas formation (most importantly, glucose and galactose; older cultures are reported to also metabolize maltose and starch). Bacteria produce both exo- and endotoxins. The role of the toxins identified in the process of melioidosis symptom development has not been fully elucidated.
Sources: en.wikipedia.org
Homosexuality is illegal in Malaysia, and authorities have imposed punishments such as caning and imprisonment. Human trafficking and sex trafficking in Malaysia are significant problems. There have also been cases of vigilante executions and beatings against LGBT individuals in Malaysia. The illegality of homosexuality in Malaysia has also been the forefront of Anwar Ibrahim's sodomy trials, which Anwar has called politically motivated, a characterisation supported by the Working Group on Arbitrary Detention, along with Amnesty International and the Human Rights Watch. The death penalty is in use for serious crimes such as murder, terrorism, and drug trafficking, some of which were once mandatory. However, in July 2023, following the passing of the Abolition of Mandatory Death Penalty Act 2023, mandatory death penalty was abolished for all crimes in Malaysia, thereby allowing judges to impose the capital punishment at their own discretion and on a case-by-case basis. The new law also abolished all natural life imprisonment, replacing it with 30 to 40 years prison terms instead.
== Development == The earliest documented signs of development began on June 18, 2007, on the modding site Mod DB. A post by "RYell", the lead developer for the game, showcased weapon models and stated that internal testing would occur during July of that year. Two months later on August 29th, a new post would showcase the Sharps Rifle 1874 and the Henry Rifle. Concept art for one of the teams, the Desperado, and in-game screenshots of the map FoF_Tramonto were shown. A month later on September 27th, an update was posted which highlighted new contributors, such as Sonic Valley Production who provided sound effects and Steve Mazzaro who composed the main theme and end round theme. The development showcased new weapons and gave a look into gameplay. Closed Beta had begun. After a few months, on December 19th, the game had been announced to release in open beta on the 21st. With main features being promised including:
On 9 January 2024, the Kata'ib Hezbollah spokesperson Jafar al-Husseini warned that the Islamic Resistance in Iraq would help Hezbollah fight Israel if war erupted between the two sides. This statement was a few weeks after the Islamic Resistance in Iraq claimed responsibility for a drone attack on a Karish rig which Lebanon claims to hold sovereignty to. On 23 June 2024, the spokesperson to Kata'ib Sayyid al-Shuhada Kadhem al-Fartousi said the brigade will join Hezbollah's side if Israel decides to launch a full-blown war in Lebanon. On 24 June 2024, Qais al-Khazali, the leader of Asa'ib Ahl al-Haq, stated in a televised speech that if the U.S. continued to support Israel in expanding the war to Lebanon and Hezbollah, the group would begin to attack US interests in Iraq and the Middle East.
All meitnerium isotopes are extremely unstable (radioactive); in general, heavier isotopes are more stable than the lighter. The most stable known isotope, 278Mt (half-life 4.5 seconds), is also the heaviest known. The unconfirmed 282Mt is even heavier and seems to have a longer half-life, 67 seconds. With a half-life of 0.8 seconds, the next most stable known isotope is 270Mt. 276Mt and 274Mt have half-lives of 0.62 and 0.64 seconds respectively. 277Mt, created as the final decay product of 293Ts for the first time in 2012, was observed to undergo spontaneous fission, half-life 5 milliseconds. Preliminary data analysis considered the possibility that this fission is instead from 277Hs, for it also has a half-life of a few milliseconds, and could come from undetected electron capture somewhere in the decay chain. This possibility was later deemed very unlikely based on observed decay energies of 281Ds and 281Rg and the short half-life of 277Mt, although there is still some uncertainty of the assignment. Regardless, the rapid fission of 277Mt and 277Hs is strongly suggestive of a region of instability for superheavy nuclei with N = 168–170. The existence of this region, characterized by a decrease in fission barrier height between the deformed shell closure at N = 162 and spherical shell closure at N = 184, is consistent with theoretical models.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.